Merck, Pfizer sign diabetes drug collaboration

04/30/2013 | Reuters · Genetic Engineering & Biotechnology News

Pfizer and Merck agreed to jointly develop and market the former's investigational type 2 diabetes drug ertugliflozin both as a standalone product and in combination with metformin and Merck's Januvia, or sitagliptin. The deal entitles Pfizer to as much as $60 million in upfront and milestone fees as well as additional payments if certain targets are reached. Merck and Pfizer said they would split potential revenue and some costs on a 60-40 basis.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL